The Plasma Protein Therapeutics Association (PPTA) represents the private sector manufacturers of plasma-derived and recombinant analog therapies, collectively known as plasma protein therapies and the collectors of source plasma used for fractionation. These therapies are used by small patient populations worldwide to treat a variety of rare diseases and serious medical conditions.
PPTA works globally to:
2016 Plasma Protein Forum Highlights +
Dr. Shari Ling, Deputy Chief Medical Officer, Centers for Medicare and Medicaid Services (CMS), delivered the Keynote opening up the 2016 PPF. Dr. Ling's remarks highlighted CMS's movement towards value based purchasing and quality based payment programs.Read More
PPTA Recognizes World PI Week: April 22-29, 2016 +
April 22, 2016—The Plasma Protein Therapeutics Association (PPTA) stands together with the global primary immunodeficiency community to promote World PI Week, a global campaign aimed to raise awareness and improve diagnosis and treatment of PID.Read More
PPTA Recognizes World Hemophilia Day–April 17, 2016 +